Header Logo

Connection

DONALD YEE to Humans

Back to Details
This is a "connection" page, showing publications DONALD YEE has written about Humans.
DONALD YEE
Connection Strength
0.248
Humans
  1. Population Pharmacokinetics of Enoxaparin in Pediatric Patients. Ann Pharmacother. 2018 02; 52(2):140-146.
    View in: PubMed
    Score: 0.014
  2. Population pharmacokinetics of human antithrombin concentrate in paediatric patients. Br J Clin Pharmacol. 2017 Nov; 83(11):2450-2457.
    View in: PubMed
    Score: 0.014
  3. The bottom (central) line in pediatric DVT. Blood. 2016 10 06; 128(14):1785-1786.
    View in: PubMed
    Score: 0.013
  4. Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis. J Pediatr. 2015 Sep; 167(3):645-9.
    View in: PubMed
    Score: 0.012
  5. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013 Nov; 52(11):967-80.
    View in: PubMed
    Score: 0.011
  6. Evaluation of weight-based dosing of unfractionated heparin in obese children. J Pediatr. 2013 Jul; 163(1):150-3.
    View in: PubMed
    Score: 0.010
  7. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013 Feb; 162(2):293-6.
    View in: PubMed
    Score: 0.010
  8. Focus on diagnosis: a primer on D-dimer. Pediatr Rev. 2011 Jan; 32(1):31-3.
    View in: PubMed
    Score: 0.009
  9. Rare bleeding disorders in young women. J Pediatr Adolesc Gynecol. 2010 Dec; 23(6 Suppl):S38-42.
    View in: PubMed
    Score: 0.009
  10. Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists. Pediatr Blood Cancer. 2009 Dec; 53(6):960-6.
    View in: PubMed
    Score: 0.008
  11. Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis. Pediatr Blood Cancer. 2009 Jul; 53(1):100-2.
    View in: PubMed
    Score: 0.008
  12. Acquired von Willebrand syndrome and Wilms tumor: not always benign. Pediatr Blood Cancer. 2009 Mar; 52(3):392-4.
    View in: PubMed
    Score: 0.008
  13. Thrombophilic conditions in the adolescent: the gynecologic impact. Obstet Gynecol Clin North Am. 2009 Mar; 36(1):163-75.
    View in: PubMed
    Score: 0.008
  14. Platelets as modifiers of clinical phenotype in hemophilia. ScientificWorldJournal. 2006 Jun 14; 6:661-8.
    View in: PubMed
    Score: 0.007
  15. A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med. 2026 Apr 09; 394(14):1388-1398.
    View in: PubMed
    Score: 0.007
  16. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005 Oct 15; 106(8):2723-9.
    View in: PubMed
    Score: 0.006
  17. Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med. 2005 Jun; 129(6):760-5.
    View in: PubMed
    Score: 0.006
  18. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
    View in: PubMed
    Score: 0.006
  19. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost. 2004 Oct; 30(5):591-600.
    View in: PubMed
    Score: 0.006
  20. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023 10 24; 7(20):6055-6065.
    View in: PubMed
    Score: 0.005
  21. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer. 2023 Mar 01; 129(5):685-696.
    View in: PubMed
    Score: 0.005
  22. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303.
    View in: PubMed
    Score: 0.005
  23. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27.
    View in: PubMed
    Score: 0.004
  24. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb Haemost. 2019 May; 119(5):844-853.
    View in: PubMed
    Score: 0.004
  25. Enoxaparin Population Pharmacokinetics in the First Year of Life. Ther Drug Monit. 2017 12; 39(6):632-639.
    View in: PubMed
    Score: 0.004
  26. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017 08 30; 117(9):1705-1713.
    View in: PubMed
    Score: 0.004
  27. Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism. Pediatr Blood Cancer. 2017 Nov; 64(11).
    View in: PubMed
    Score: 0.004
  28. Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk? J Pediatr Hematol Oncol. 2017 03; 39(2):121-125.
    View in: PubMed
    Score: 0.003
  29. Assessment of an Electronic Intervention in Young Women with Heavy Menstrual Bleeding. J Pediatr Adolesc Gynecol. 2017 Apr; 30(2):243-246.
    View in: PubMed
    Score: 0.003
  30. Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. J Pediatr Hematol Oncol. 2016 Mar; 38(2):139-42.
    View in: PubMed
    Score: 0.003
  31. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood. 2015 Dec 10; 126(24):2541-7.
    View in: PubMed
    Score: 0.003
  32. Quantification of Hydroxylated Polybrominated Diphenyl Ethers (OH-BDEs), Triclosan, and Related Compounds in Freshwater and Coastal Systems. PLoS One. 2015; 10(10):e0138805.
    View in: PubMed
    Score: 0.003
  33. Oral Tranexamic Acid versus Combined Oral Contraceptives for Adolescent Heavy Menstrual Bleeding: A Pilot Study. J Pediatr Adolesc Gynecol. 2015 Aug; 28(4):254-7.
    View in: PubMed
    Score: 0.003
  34. Hemostatic abnormalities in young females with heavy menstrual bleeding. J Pediatr Adolesc Gynecol. 2014 Dec; 27(6):324-9.
    View in: PubMed
    Score: 0.003
  35. Age-related differences in urinary 11-dehydroxythromboxane B2 between infants, children, and adolescents: another example of developmental hemostasis? Pediatr Blood Cancer. 2014 Nov; 61(11):2074-6.
    View in: PubMed
    Score: 0.003
  36. Catheter-directed thrombolysis for severe pulmonary embolism in pediatric patients. Ann Vasc Surg. 2014 Oct; 28(7):1794.e1-7.
    View in: PubMed
    Score: 0.003
  37. Molecular link between intravascular hemolysis and vascular occlusion in sickle cell disease. Curr Vasc Pharmacol. 2012 Nov; 10(6):756-61.
    View in: PubMed
    Score: 0.003
  38. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54.
    View in: PubMed
    Score: 0.002
  39. Recurrent menorrhagia in an adolescent with a platelet secretion defect. J Pediatr Adolesc Gynecol. 2011 Apr; 24(2):e35-8.
    View in: PubMed
    Score: 0.002
  40. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4.
    View in: PubMed
    Score: 0.002
  41. A practical approach to pediatric patients referred with an abnormal coagulation profile. Arch Pathol Lab Med. 2005 Aug; 129(8):1011-6.
    View in: PubMed
    Score: 0.002
  42. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.